Leukotriene receptor antagonists in achieving control of bronchial asthma associated with allergic rhinitis
Meditsinskiy sovet = Medical Council · 14.07.2026 · (9) · 209-217
DOI: 10.21518/ms2026-148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Meditsinskiy sovet = Medical Council, online erschienen am 14.07.2026. Verfasst von M. Yu. Korkmazov. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
The comorbidity of bronchial asthma and allergic rhinitis remains one of the most significant problems of respiratory medicine, since these diseases often coexist and mutually aggravate each other’s course. For example, nasal obstruction, postnasal congestion, breathing through the mouth, seasonal increase in symptoms of allergic rhinitis and stress-induced cough often create the impression of unstable asthma even when inhalation therapy is correctly selected. In this context, leukotriene receptor antagonists are of particular interest, primarily Ektalust (the active ingredient is montelukast), which remain in practical demand in some patients with the asthma + allergic rhinitis phenotype, not only as drugs that reduce bronchospasm, but also as agents for nasal obstruction, rhinorrhea, itching and sneezing. The Russian Clinical Guidelines for Allergic Rhinitis of 2024 suggest that such patients should be prescribed them for antiallergic, anti–inflammatory and anti-asthmatic effects, noting the high levels of persuasiveness of recommendation (A) and reliability of evidence (1). The commentary to the recommendation explicitly states that their use allows you to control the symptoms of both diseases and avoid polypragmasia. At the same time, the practical use of leukotriene receptor blockers requires proper positioning, since they are not a means of relieving an acute asthma attack, should not replace inhaled glucocorticosteroids, and are not considered as a universal starting therapy for allergic rhinitis. The key aspect of the article is the analysis of treatment in three different clinical cases using Ektalust and the answer to the question due to which pathogenetic and organizational mechanisms a positive clinical effect was achieved. Special emphasis is placed on the greatest value of the drug not as a universal control tool, but as a tool for personalized therapy in patients with asthma and comorbid conditions.
Zitieren
APA
Korkmazov, M. Y. (2026). Leukotriene receptor antagonists in achieving control of bronchial asthma associated with allergic rhinitis. Meditsinskiy sovet = Medical Council, 209-217. https://doi.org/10.21518/ms2026-148
Vancouver
Korkmazov MY. Leukotriene receptor antagonists in achieving control of bronchial asthma associated with allergic rhinitis. Meditsinskiy sovet = Medical Council. 2026:209-217. doi:10.21518/ms2026-148
BibTeX
@article{Korkmazov2026,
author = {Korkmazov, M. Yu.},
title = {Leukotriene receptor antagonists in achieving control of bronchial asthma associated with allergic rhinitis},
journal = {Meditsinskiy sovet = Medical Council},
year = {2026},
number = {9},
pages = {209--217},
doi = {10.21518/ms2026-148}
}
EUVIMED